#1 Clinical Trials Search in Europe

Opportunities for Healthy Volunteers

Contribute to medical research by participating in studies designed for healthy participants in your selected area.

↓

Matched clinical trials

  • Gedatolisib plus drug combination for HR‑positive, HER2‑negative advanced breast cancer patients whose disease progressed after CDK4/6 inhibitor therapy

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Austria Belgium Bulgaria Czechia France Germany +6

  • Study on the Effects of Ribociclib and Endocrine Therapy for Patients with HR-Positive, HER2-Negative Early Breast Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Germany Portugal

  • Study of Elacestrant and Ribociclib for Patients with Endocrine-Responsive HER2-Negative Early Breast Cancer

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    Austria Germany

  • Study on Abemaciclib, Letrozole, and Fulvestrant for Patients with Advanced HR-positive/HER2-negative Breast Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Italy Portugal Spain

  • Study on Niraparib for Patients with HER2-Negative BRCA-Mutated or Triple-Negative Breast Cancer with Molecular Disease Detected by ctDNA

    Not recruiting

    3 1
    Investigated Diseases:
    Investigated Drugs:
    Italy The Netherlands Poland Spain

  • Title: Study of everolimus with hormone therapy in women with high-risk breast cancer (ER-positive, HER2-negative) who are disease-free after initial treatment

    Not recruiting

    3 1 1
    Investigated Diseases:
    Investigated Drugs:
    Belgium France

  • Study on Abemaciclib and Endocrine Therapy for Patients with Advanced Hormone Receptor Positive HER2 Negative Breast Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Germany

  • Study Comparing Ribociclib and Palbociclib for Patients with Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Portugal Spain

  • Study Comparing Trastuzumab Deruxtecan with Chemotherapy for Patients with HER2-Low, Hormone Receptor Positive Breast Cancer After Endocrine Therapy Progression

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Austria Belgium Denmark France Germany Hungary +6

  • Study on Alpelisib and Fulvestrant for Advanced Breast Cancer in Patients with PIK3CA Mutation and Hormone-Receptor Positive, HER2 Negative Tumors

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    The Netherlands